Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;42(4):549-61.
doi: 10.1053/j.seminoncol.2015.05.006. Epub 2015 Jun 3.

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

Joseph Obeid  1 , Yinin Hu  1 , Craig L Slingluff Jr  2
Affiliations
Review

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

Joseph Obeid et al. Semin Oncol. 2015 Aug.

Abstract

Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies, there is renewed enthusiasm for optimizing cancer vaccines for use to prevent recurrence in early-stage cancers and/or to combine with other immune therapies for therapy of advanced cancers. Future advancements in vaccine therapy will involve the identification and selection of effective antigen formulations, optimization of adjuvants, dendritic cell (DC) activation, and combination therapies. In this summary we present the current practice, the broad collection of challenges, and the promising future directions of vaccine therapy for cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer vaccine trials listed as open at ClinicalTrials.gov September 2014. The number of trials for each cancer type are shown in the bar graph. The number with each type of antigen presentation is shown in the inset table. RCC = renal cell carcinoma; CRC = colorectal cancer; HNSCC = head and neck squamous cell carcinoma.
Figure 2
Figure 2
Types of cancer antigens, with examples for each.
Figure 3
Figure 3
Adjuvants being used in clinical trials of cancer vaccines. Cancer vaccine trials listed as open at Clinical Trials.gov (Sept 2014) were assessed for the adjuvants used, showing the number of trials with each A) local and B) systemic vaccine adjuvants. IFA = incomplete Freund’s adjuvant; IL-12 = interleukin-12; CD40L = CD40 ligand; Cy = cyclophosphamide; IDOi = indoleamine-2,3-dis=oxygenase inhibitor; CT-011 and nivolumab are PD-1 antibodies.
Figure 4
Figure 4
Cancer vaccines commonly employ agents that induce “danger” by mimicking foreign pathogens.
See this image and copyright information in PMC

References

    1. Denkert C, von MG, Brase JC, et al. Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. J Clin Oncol. 2014 JCO. - PubMed
    1. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. - PubMed
    1. Erdag G, Schaefer JT, Smolkin ME, et al. Immunotype and immunohistologic characteristics of tumor infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012;72:1070–1080. - PMC - PubMed
    1. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393–402. - PubMed
    1. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT., Jr Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012;35:385–389. - PMC - PubMed

Publication types

MeSH terms